Home › Research › Digital health tools
Individual Angiotensin Receptor Blockers and Risk of Dementia: A Target Trial Emulation Study
Hampilos NH, Campion TR, Sholle E, Zang C, Glodzik L, Butler TA, Ndhlovu LC.. medRxiv, 2026-10-14
Topic: Drug trials: efficacy and safety
Plain-language summary
Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years. Pooled ARBs were associated with lower dementia risk than lisinopril (HR, 0.86; 95% CI, 0.85 to 0.87), with substantial variation across individual agents (HR range, 0.66 to 0.93). Within-class comparisons showed similar heterogeneity (HR range, 0.68 to 0.94) and reproduced between-class agent ordering by HR estimates. Considerable agent-level variation was also observed across secondary outcomes. Losartan, the most commonly prescribed ARB, had the least favorable dementia associations. Negative-control associations were near null within class, and sensitivity analyses supported robustness. Individual ARBs were associated with differing dementia risks, suggesting clinically relevant within-class heterogeneity pending confirmation in randomized trials.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Hampilos, N. H., Campion, T. R., Sholle, E., Zang, C., Glodzik, L., Butler, T. A., et al. (2026). Individual Angiotensin Receptor Blockers and Risk of Dementia: A Target Trial Emulation Study. medRxiv. https://doi.org/10.64898/2026.10.13.26365306
Vancouver
Hampilos NH, Campion TR, Sholle E, Zang C, Glodzik L, Butler TA, et al. Individual Angiotensin Receptor Blockers and Risk of Dementia: A Target Trial Emulation Study. medRxiv. 2026. doi:10.64898/2026.10.13.26365306.
BibTeX
@article{hampilos2026-4a696e60,
author = {Hampilos, N. H. and Campion, T. R. and Sholle, E. and Zang, C. and Glodzik, L. and Butler, T. A. and Ndhlovu, L. C.},
title = {{Individual Angiotensin Receptor Blockers and Risk of Dementia: A Target Trial Emulation Study}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.10.13.26365306},
url = {https://doi.org/10.64898/2026.10.13.26365306}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Of 22,025,599 individuals screened, 2,051,275 were eligible; matched cohorts ranged from 10,113 to 857,773, with median follow-up of 4.7 to 7.2 years.
- Pooled ARBs were associated with lower dementia risk than lisinopril (HR, 0.86; 95% CI, 0.85 to 0.87), with substantial variation across individual agents (HR range, 0.66 to 0.93).
- Within-class comparisons showed similar heterogeneity (HR range, 0.68 to 0.94) and reproduced between-class agent ordering by HR estimates.
- Considerable agent-level variation was also observed across secondary outcomes.
- Losartan, the most commonly prescribed ARB, had the least favorable dementia associations.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Study designcohort study
- Evidence strengthHigh
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 39 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 24 of the 62 points we could judge it on, which is 39 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 24 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 24 of the 62 points we could judge it on is 39 out of 100. |
| Total | 39 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Digital health tools from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.